HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

[Intravenous and oral treatment with amantadine sulfate in Parkinson disease].

Abstract
The rapid efficacy of amantadine on akinesia and rigidity in Parkinson's disease is generally known. The duration of this therapeutic result is however controversial. Some authors have reported a loss of efficacy after only a few weeks of therapy. The success of a short-term parenteral and subsequently oral long-term treatment with amantadine sulphate in 8 Parkinsonian patients was tested by means of clinical and neuropsychological examinations and by monitoring the serum concentration over the course of half a year. A ten-day intravenous treatment with amantadine sulphate (200 mg daily) led to a significant improvement in the clinical and psychological test results. This attained improvement could be maintained for 6 months with oral therapy consisting of 600 mg amantadine sulphate. There were strong interindividual variations in serum concentration.
AuthorsM Brenner, A Haass, P Jacobi, K Schimrigk
JournalDer Nervenarzt (Nervenarzt) Vol. 59 Issue 3 Pg. 180-4 (Mar 1988) ISSN: 0028-2804 [Print] GERMANY, WEST
Vernacular TitleIntravenöse und orale Behandlung mit Amantadinsulfat bei der Parkinsonkrankheit.
PMID3374720 (Publication Type: English Abstract, Journal Article)
Chemical References
  • Amantadine
Topics
  • Administration, Oral
  • Amantadine (administration & dosage, pharmacokinetics)
  • Female
  • Humans
  • Infusions, Intravenous
  • Male
  • Middle Aged
  • Neuropsychological Tests
  • Parkinson Disease (blood, drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: